Clinical Trials Logo
  1. Home
  2. Alpha 1-Antitrypsin Deficiency
  3. NCT00005098
  4. Details
NCT00005098 Clinical Trial

Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency

Alpha 1-Antitrypsin Deficiency Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00005098
Other study ID # 199/14810
Secondary ID WUSM-930603
Status Terminated
Phase N/A
First received April 6, 2000
Last updated June 23, 2005
Start date March 1999

Study information
Verified date May 2002
Source National Center for Research Resources (NCRR)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

OBJECTIVES:

I. Establish cell lines from patients with alpha 1-antitrypsin deficiency in order to examine genetic traits that predispose to liver injury.

Description:

PROTOCOL OUTLINE:

Patients undergo blood draw and skin biopsy. Cells are isolated from patients' blood and skin, cell lines are established, and genetic traits are examined.

Recruitment information / eligibility
Status Terminated
Enrollment 160
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility - Alpha 1-antitrypsin deficiency

Study Design

Primary Purpose: Screening

Related Conditions & MeSH terms

Locations
Country Name City State
United States Children's Hospital of Pittsburgh Pittsburgh Pennsylvania

Sponsors (2)
Lead Sponsor Collaborator
National Center for Research Resources (NCRR) Children's Hospital of Pittsburgh

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT03285100 - The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation N/A
Completed NCT03636347 - A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Phase 2
Completed NCT00396006 - Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor) Phase 4
Completed NCT04174118 - Study of DCR-A1AT in Healthy Adult Volunteers Phase 1
Completed NCT05579431 - A Phase 1, First-in-human Study of VX-634 Phase 1
Recruiting NCT05856331 - Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema Phase 2
Recruiting NCT00571272 - Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Completed NCT02168686 - Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency Phase 1/Phase 2
Recruiting NCT04204252 - Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD Phase 3
Completed NCT00067756 - 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency? Phase 2
Not yet recruiting NCT06389877 - A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) Phase 1/Phase 2
Completed NCT00295061 - Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Phase 3
Completed NCT00001462 - Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals N/A
Active, not recruiting NCT05297812 - Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
Completed NCT03114020 - Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency Phase 2
Completed NCT00460096 - Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Phase 2/Phase 3
Completed NCT00377416 - Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency Early Phase 1
Completed NCT03362242 - Study of ARO-AAT in Normal Adult Volunteers Phase 1
Not yet recruiting NCT05897424 - Open Label Extension Study of INBRX-101 in Adults With AATD Emphysema Phase 2